Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,656 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Growth Clear all
Terminated Phase 2 Interventional Results available

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

NCT04172597
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
Interventions
Poziotinib Hydrochloride, Loperamide
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 25, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

NCT01866410
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Cabozantinib S-malate, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 25, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Predictors of Aortic Aneurysm Growth and Rupture

NCT02022436
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
Contrast Ultrasound
Drug
Lead sponsor
Rabih A. Chaer
Other
Eligibility
21 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 25, 2026, 9:08 PM EDT
Completed Phase 1 Interventional

Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy

NCT00486304
View directory record Official record
Conditions
Cachexia, Head and Neck Cancer, Weight Changes
Interventions
ADD, Placebo
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Oct 25, 2026, 9:08 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

NCT01912963
View directory record Official record
Conditions
HER2-positive Breast Cancer, Metastatic Breast Cancer
Interventions
Pertuzumab, Trastuzumab, eribulin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 25, 2026, 9:08 PM EDT
Terminated No phase listed Observational Results available

A Clinical Registry to Collect Patient Outcome Date for the BIOMET® Stimulator Systems

NCT01750840
View directory record Official record
Conditions
Fusion of Spine (Disease), Fractures, Ununited
Interventions
Biomet® EBI Bone Healing System, Biomet Orthopak® Non-Invasive Bone Growth Stimulator System, Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Vineland, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 25, 2026, 9:08 PM EDT
Completed No phase listed Observational

Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents

NCT01976078
View directory record Official record
Conditions
Pharmacokinetics, Voriconazole
Interventions
Midazolam/Ranitidine/Esomeprazole
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 25, 2026, 9:08 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Does the Cerebroplacental Ratio (CPR) Predict Adverse Outcomes in Low Risk Pregnancies?

NCT03066726
View directory record Official record
Conditions
Cerebroplacental Ratio
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
6
States / cities
New Brunswick, New Jersey • Sewell, New Jersey • Flushing, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 25, 2026, 9:08 PM EDT
Terminated No phase listed Observational

A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

NCT05894876
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
No treatment is given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 11 Years
Enrollment
43 participants
Timeline
2024 – 2025
U.S. locations
2
States / cities
Orange, California • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 25, 2026, 9:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Whole Foods Supplementation on Cognition

NCT01672359
View directory record Official record
Conditions
Sub-optimal Cognitive Function, Sub-optimal Immune Function
Interventions
Ginkgo Synergy® and Choline, OPC Synergy® and Catalyn, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
60 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 25, 2026, 9:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair

NCT03206567
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol Supplement capsules, Placebo capsules
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 25, 2026, 9:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Growth Hormone Resistance of Beta-cells in People With a Family History of Type 2 Diabetes

NCT06571500
View directory record Official record
Conditions
Healthy, Obesity
Interventions
Not listed
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 25, 2026, 9:08 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dietary Protein in the Very-low-birth-weight Infant

NCT01208493
View directory record Official record
Conditions
Prematurity
Interventions
preterm infant formula with high protein levels, preterm standard infant formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
1 Day to 10 Weeks
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 25, 2026, 9:08 PM EDT
Completed Phase 1Phase 2 Interventional

HCW9218 for Advanced Pancreatic Cancer

NCT05304936
View directory record Official record
Conditions
Advanced Pancreatic Carcinoma
Interventions
HCW9218, Gemcitabine (GEM), Nab-paclitaxel
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Scottsdale, Arizona • Bethesda, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 25, 2026, 9:08 PM EDT
Recruiting Phase 2 Interventional

A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

NCT02491099
View directory record Official record
Conditions
HER2/Neu+ Uterine Serous Carcinoma
Interventions
Afatinib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
3
States / cities
Tucson, Arizona • New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 25, 2026, 9:08 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

NCT03410693
View directory record Official record
Conditions
Carcinoma, Transitional Cell
Interventions
Rogaratinib (BAY1163877), Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 25, 2026, 9:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serum and Urine Titanium Levels in Children With Early Onset Scoliosis Treated With Growth-Sparing Instrumentation

NCT04069637
View directory record Official record
Conditions
Early-Onset Scoliosis Deformity of Spine
Interventions
Growth-sparing instrumentation and titanium levels
Combination Product
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 15 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 25, 2026, 9:08 PM EDT
Active, not recruiting Phase 4 Interventional

Roll-over Study to Allow Continued Access to Ribociclib

NCT05161195
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
16
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 9:08 PM EDT
Completed No phase listed Observational

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

NCT06961331
View directory record Official record
Conditions
Metastatic HER2+ Advanced Breast Cancer
Interventions
Tucatinib, Trastuzumab, Capecitabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 25, 2026, 9:08 PM EDT
Not listed Phase 2Phase 3 Interventional

Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients

NCT02296567
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Ranibizumab, Bevacizumab, Aflibercept, Control Group
Drug · Other
Lead sponsor
East Florida Eye Institute
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stuart, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 25, 2026, 9:08 PM EDT
Recruiting Not applicable Interventional

Integrated Treatment for Enhancing Growth in Recovery During Adolescence

NCT06395467
View directory record Official record
Conditions
Alcohol Use Disorder, Cannabis Use Disorder
Interventions
InTEGRA, MET/CBT
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 21 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Farmington, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 25, 2026, 9:08 PM EDT
Active, not recruiting Not applicable Interventional

The Development of Eating Behavior in Infancy: Associations With Behavior, Diet, and Growth at School Age

NCT04723264
View directory record Official record
Conditions
Eating Behavior
Interventions
Food protocols
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
5 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 25, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer

NCT00217672
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, Docetaxel
Biological · Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 25, 2026, 9:08 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

NCT00999557
View directory record Official record
Conditions
Alopecia, Breast Cancer
Interventions
bimatoprost ophthalmic solution, placebo
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 25, 2026, 9:08 PM EDT